MAO/EVALUATION OF AIDS VACCINES

艾滋病毒临床前疫苗开发主协议计划是 启动以使NIAID能够提供资源以加速 开发有前景的疫苗方法。在这个计划下，一系列 已经启动了疫苗研究，以评估候选疫苗和 非人灵长类动物的艾滋病疫苗原型。这些研究是专门设计的 获取更多有关疗效和最佳呈现方式的信息 正在进行人类第一阶段临床试验的候选艾滋病毒疫苗或 建议用于此类试验以及该试验的SIV疫苗原型 作为这些艾滋病毒疫苗的类型。其他疫苗研究将评估原型 提供新颖呈现系统的HIV或SIV疫苗可能能够 引发广泛的交叉反应免疫反应，或者已经显示出 有希望的初步结果。NIAID已经启动了协作 与同意提供艾滋病毒和SIV的研究人员的安排 非人灵长类动物免疫疫苗。在所有疫苗中 非人灵长类动物在免疫后将受到挑战的研究 确定是否可以获得免受感染或疾病的保护。 主协议项目B类承包商。包括 上述承包商将提供住房和照顾，以进行免疫和 挑战非人类灵长类动物进行各种疫苗研究。这个 承包商将从以下地点获得血清细胞和其他适当的样本 参与研究的动物，并将视情况将样本运往 评估体液免疫反应的承包商包括 中和抗体用于评估细胞免疫反应和 用于挑战后的病毒学评估。B类承建商 将为他们正在进行的每项研究维护一个数据库，以便 遵循免疫方案病毒挑战，所有的化验 研究中每只猴子的结果。

The HIV Preclinical Vaccine Development Master Agreement Program was initiated to enable the NIAID to provide resources to accelerate the development of promising vaccine approaches. Under this program a series of vaccine studies have been initiated to evaluate candidate and prototype AIDS vaccines in nonhuman primates. These studies are designed to obtain more information about the efficacy and optimum presentation of candidate HIV vaccines that are in human Phase I clinical trials or proposed for such trials as well as prototype SIV vaccines of the same type as these HIV vaccines. Other vaccine studies will evaluate prototype HIV or SIV vaccines that offer novel presentation systems, may be capable of eliciting broadly cross-reactive immune responses, or have shown promising preliminary results. NIAID has initiated collaborative arrangements with researchers who have agreed to provide HIV and SIV vaccines for immunization of nonhuman primates. In all of the vaccine studies the nonhuman primates will be challenged after immunization to determine if protection from infection or from disease can be obtained. The contractors in Category B of the Master Agreement Program. including the contractor listed above, will provide house and care for immunize and challenge the nonhuman primates for the various vaccine studies. The contractors will obtain sera cells, and other appropriate samples from the animals in the studies and will ship the samples, as appropriate, to contractors for evaluation of humoral immune responses including neutralizing antibodies for evaluation of cellular immune responses and for virological assessment after challenge. The category B contractors will maintain a data base for each study they are conducting in order to follow the immunization protocol virus challenge, and all the assay results for each monkey in the study.